Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 20/20 | 1.00 |
| ▸ | THRB | P10828 | 10/20 | 0.77 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.77 |
| ▸ | TGFBR2 | P37173 | 3/20 | 0.73 |
| ▸ | GAK | O14976 | 1/20 | 0.73 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.73 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.73 |
| ▸ | KDR | P35968 | 1/20 | 0.73 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.73 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.73 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.73 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.73 |
| ▸ | TGFB2 | P61812 | 1/20 | 0.73 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.73 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.73 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.73 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.73 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31461242 | 1.00 | TGFBR1 (1.00) | TGFBR1THRBMAPK14TGFBR2GAK | |
| SCHEMBL414104 | 0.93 | TGFBR1 (0.86) | TGFBR1THRBMAPK14TGFBR2GAK | |
| SCHEMBL12922146 | 0.90 | TGFBR1 (0.82) | TGFBR1THRBMAPK14TGFBR2GAK | |
| SCHEMBL23852042 | 0.89 | TGFBR1 (0.80) | TGFBR1THRBMAPK14TGFBR2GAK | |
| SCHEMBL1027982 | 0.89 | TGFBR1 (0.80) | TGFBR1THRBMAPK14TGFBR2GAK | |
| SCHEMBL31461245 | 0.89 | TGFBR1 (0.80) | TGFBR1THRBMAPK14TGFBR2GAK | |
| SCHEMBL5240012 | 0.89 | TGFBR1 (0.80) | TGFBR1THRBMAPK14TGFBR2GAK | |
| Water SCHEMBL1029466 | 0.88 | TGFBR1 (0.78) | TGFBR1THRBMAPK14TGFBR2GAK | |
| SCHEMBL373314 | 0.87 | TGFBR1 (1.00) | TGFBR1THRBMAPK14TGFBR2GAK | |
| SCHEMBL29740016 | 0.87 | TGFBR1 (1.00) | TGFBR1THRBMAPK14TGFBR2GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1397364-B1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | LILLY CO ELI (US) | 2007-07-25 | — | — | EP | claimed |
| CN-1269820-C | Novel pyrrole derivatives as medicaments | LILLY CO ELI (US) | 2006-08-16 | — | — | CN | claimed |
| CN-1511157-A | Novel pyrrole derivatives as medicaments | — | 2004-07-07 | — | — | CN | claimed |
| EP-1397364-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-03-17 | — | — | EP | claimed |
| WO-2002094833-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2002-11-28 | — | — | WO | claimed |
| US-20220089600-A1 | TGFß INHIBITOR AND PRODRUGS | FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA) (ES) | 2022-03-24 | — | — | US | disclosed |
| EP-3883556-A2 | TGF? INHIBITOR AND PRODRUGS | Fundació Institut de Recerca Biomèdica IRB (Barcelona) (ES) | 2021-09-29 | — | — | EP | disclosed |
| CN-113347965-A | TGF-beta inhibitors and prodrugs | 生物医学研究机构基金会 | 2021-09-03 | — | — | CN | disclosed |
| US-20160115447-A1 | COMPOSITIONS AND METHODS FOR IMPROVING INDUCED NEURON GENERATION | HOWARD HUGHES MEDICAL INSTITUTE | 2016-04-28 | — | — | US | disclosed |
| US-8871744-B2 | Compounds and methods for selectively targeting tumor-associated mucins | B & G Partyers, LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140120621-A1 | TGF-BETA RECEPTOR INHIBITORS TO ENHANCE DIRECT REPROGRAMMING | THE GENERAL HOSPITAL CORPORATION (US) | 2014-05-01 | — | — | US | disclosed |
| US-8603818-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2013-12-10 | — | — | US | disclosed |
| US-20060040983-A1 | Quinolinyl-pyrrolopyrazoles | ELI LILLY AND COMPANY (US) | 2006-02-23 | — | — | US | disclosed |
| CN-1714090-A | Quinolinyl-pyrrolopyrazoles | LILLY CO ELI (US) | 2005-12-28 | — | — | CN | disclosed |
| EP-1565471-A1 | QUINOLINYL-PYRROLOPYRAZOLES | ELI LILLY AND COMPANY (US) | 2005-08-24 | — | — | EP | disclosed |
| CN-1511157-A | Novel pyrrole derivatives as medicaments | — | 2004-07-07 | — | — | CN | disclosed |
| WO-2004048382-A1 | QUINOLINYL-PYRROLOPYRAZOLES | ELI LILLY AND COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY | 2004-06-03 | — | — | US | disclosed |
| EP-1397364-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002094833-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089600-A1 | TGFß INHIBITOR AND PRODRUGS | TGFB1, TGFBR1, TGFBR2 | TGFBR1 2/4885THRB 89/4885MAPK14 185/4885 |
| US-20060040983-A1 | Quinolinyl-pyrrolopyrazoles | SDHA, NQO2, SDHB | TGFBR1 4885/4885THRB 4526/4885MAPK14 2460/4885 |
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | TGFBR1, SMAD3, TGFBR2 | TGFBR1 1/4885THRB 500/4885MAPK14 546/4885 |
| US-20160115447-A1 | COMPOSITIONS AND METHODS FOR IMPROVING INDUCED NEURON GENERATION | PLK1, GAP43, NEFM | TGFBR1 2217/4885THRB 2669/4885MAPK14 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.